- Home
- DSGN vs CYRX Comparison
DSGN vs CYRX Comparison
Compare DSGN & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- CYRX
- Stock Information
- Founded
- DSGN 2017
- CYRX 1999
- Country
- DSGN United States
- CYRX United States
- Employees
- DSGN N/A
- CYRX N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- CYRX Health Care
- Exchange
- DSGN Nasdaq
- CYRX Nasdaq
- Market Cap
- DSGN 353.9M
- CYRX 381.6M
- IPO Year
- DSGN 2021
- CYRX N/A
- Fundamental
- Price
- DSGN $6.25
- CYRX $7.86
- Analyst Decision
- DSGN Hold
- CYRX Buy
- Analyst Count
- DSGN 3
- CYRX 7
- Target Price
- DSGN $7.00
- CYRX $13.14
- AVG Volume (30 Days)
- DSGN 208.4K
- CYRX 446.9K
- Earning Date
- DSGN 11-07-2024
- CYRX 11-07-2024
- Dividend Yield
- DSGN N/A
- CYRX N/A
- EPS Growth
- DSGN N/A
- CYRX N/A
- EPS
- DSGN N/A
- CYRX N/A
- Revenue
- DSGN N/A
- CYRX $226,113,000.00
- Revenue This Year
- DSGN N/A
- CYRX N/A
- Revenue Next Year
- DSGN N/A
- CYRX $7.92
- P/E Ratio
- DSGN N/A
- CYRX N/A
- Revenue Growth
- DSGN N/A
- CYRX N/A
- 52 Week Low
- DSGN $2.25
- CYRX $5.32
- 52 Week High
- DSGN $7.77
- CYRX $20.11
- Technical
- Relative Strength Index (RSI)
- DSGN 52.38
- CYRX 53.97
- Support Level
- DSGN $5.55
- CYRX $7.44
- Resistance Level
- DSGN $6.45
- CYRX $8.37
- Average True Range (ATR)
- DSGN 0.56
- CYRX 0.63
- MACD
- DSGN -0.04
- CYRX 0.02
- Stochastic Oscillator
- DSGN 57.67
- CYRX 51.66
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.